Skip to main content

Table 2 Clinical trials in promising cancer target of PVR like receptors

From: Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy

NCT Number Target Agent Estimated Enrollment Phase Condition Recruitment Statue Estimated Study Completion Date
NCT04099277 DNAM-1 LY3435151 2 aI/b1 Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma Terminated May 5, 2020
NCT04656535 TIGIT AB154 46 0/I Glioblastoma Not yet recruiting Jul, 2023
NCT03628677 TIGIT AB154 66 I Solid Tumor, Unspecified, Adult Recruiting Nov 10, 2021
NCT04262856 TIGIT AB154 150 II Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cance Recruiting Jun 23, 2022
NCT04736173 TIGIT AB154 625 III Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Lung Cancer Recruiting Jun 30, 2026
NCT03945253 TIGIT ASP8374 6 I Advanced Solid Tumors Completed Jun 12, 2020
NCT03260322 TIGIT ASP8374 169 I Advanced Solid Tumors Active, not recruiting Mar, 2022
NCT04693234 TIGIT BGB-A1217 167 II Cervical Cancer Not yet recruiting Mar 31, 2023
NCT04732494 TIGIT BGB-A1217 280 II Esophageal Squamous Cell Carcinoma Recruiting Mar, 2024
NCT04047862 TIGIT BGB-A1217 234 I Locally Advanced, Metastatic Solid Tumors Recruiting Aug, 2023
NCT04746924 TIGIT BGB-A1217 605 III Non-small Cell Lung Cancer Not yet recruiting Mar, 2025
NCT04150965 TIGIT BMS-986207 104 I/II Multiple Myeloma, Relapsed Refractory Multiple Myeloma Recruiting Mar 30, 2022
NCT04354246 TIGIT COM902 45 I Advanced Cancer, Ovarian Cancer; Lung Cancer, Colon Cancer; Plasma Cell Neoplasm, Breast Cancer Recruiting Sep 30, 2022
NCT04353830 TIGIT IBI939 270 Ia/Ib Advanced Malignancies Recruiting Dec 31, 2023
NCT04672369 TIGIT IBI939 36 I Advanced Lung Cancer Not yet recruiting Oct 9, 2024
NCT04672356 TIGIT IBI939 20 I Advanced Lung Cancer Recruiting Nov 9, 2024
NCT04457778 TIGIT M6223 35 I Metastatic Solid Tumors Recruiting Sep 14, 2022
NCT04305054 TIGIT MK-7684 315 I/II Melanoma Recruiting Apr 3, 2030
NCT04305041 TIGIT MK-7684 200 I/II Melanoma Recruiting Apr 3, 2030
NCT04303169 TIGIT MK-7684 65 I/II Melanoma Recruiting Apr 3, 2030
NCT04761198 TIGIT MPH313 125 I/II Solid Tumor, Adult Advanced Solid Tumor, Metastatic Solid Tumor Recruiting Jun 30, 2023
NCT04543617 TIGIT MTIG7192A 750 III Esophageal Squamous Cell Carcinoma Recruiting Dec 26, 2025
NCT04256421 TIGIT MTIG7192A 470 III Small Cell Lung Cancer Recruiting Sep 29, 2023
NCT04294810 TIGIT MTIG7192A 560 III Non-Small Cell Lung Cancer Recruiting Feb 21, 2025
NCT03708224 TIGIT MTIG7192A 55 II Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer Recruiting Nov 30, 2025
NCT03563716 TIGIT MTIG7192A 135 II Non-small Cell Lung Cancer Active, not recruiting Oct 30, 2021
NCT03281369 TIGIT MTIG7192A 410 I/II Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Recruiting Feb 11, 2023
NCT03119428 TIGIT OMP-31 M32 33 I Locally Advanced Cancer, Metastatic Cancer Terminated May 15, 2019
NCT04254107 TIGIT SGN-TGT 231 I Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma; Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer Recruiting Mar 31, 2023
NCT04570839 CD112R COM701 100 I/II Endometrial Neoplasms, Ovarian Cancer, solid Tumor Recruiting Dec, 2023
NCT03667716 CD112R COM701 140 I Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer Recruiting Dec, 2021